Insoluble drug delivery strategies: Review of recent advances and business prospects

Acta Pharmaceutica Sinica B

Volumn 5, Issue 5, 2015, Pages 442-453

  Kalepu, Sandeep ^a   Nekkanti, Vijaykumar ^b  

^a SHRI VISHNU COLLEGE OF PHARMACY   (India)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Bioavailability; Cocrystals; Inclusion complexation; Nanoparticles; Proliposomes; Self emulsifying formulations; Solubility

Indexed keywords

APREPITANT; CHLORDIAZEPOXIDE; CISPLATIN; CYCLODEXTRIN DERIVATIVE; DEXMETHYLPHENIDATE; DIHYDROERGOTAMINE; DOXORUBICIN; DOXYCYCLINE; ESTRADIOL; ETRAVIRINE; FENOFIBRATE; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR; LORAZEPAM; MACROGOL; MEGESTROL ACETATE; METHOCARBAMOL; METHYLPHENIDATE; MORPHINE SULFATE; NABILONE; NIMODIPINE; PACLITAXEL; POLYLACTIC ACID; PROPANIDID; RAPAMYCIN; SOLID LIPID NANOPARTICLE; TACROLIMUS; TENIPOSIDE; TIZANIDINE; UNINDEXED DRUG;

COMPLEX FORMATION; CRITICAL MICELLE CONCENTRATION; CRYSTALLIZATION; DISPERSION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; ENCAPSULATION; EXCIPIENT COMPATIBILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IONIZATION; MICROEMULSION; PARTICLE SIZE; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SALINITY;

EID: 84946149088     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2015.07.003     Document Type: Review

References (110)

1. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010, 62:1607-1621.
2. Hodgson J. ADMET-turning chemicals into drugs. Nat Biotechnol 2001, 19:722-726.
3. The 505(b)(2) blog. 2012 approvals. Available from: . http://www.blog.camargopharma.com/index.php/scorecard/2012-approvals.
4. Drews J, Ryser S. Innovation deficit in the pharmaceutical industry. Drug Inf J 1996, 30:97-108.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, applications covered by section 505(b)(2). Rockville, MD 20857: 1999.
6. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deivl Rev 2007, 59:603-616.
7. http://www.rxlist.com/cipro-iv-drug.htm.
8. http://www.rxlist.com/micardis-drug.htm.
9. Hauel N, Narr B, Ries U, Van Meel JC, Wienen W, Entzeroth M, inventors; Karl Thomae GmbH, assignee. Benzimidazoles useful as angiotensin-11 antagonists. United States Patent US 5591762. Januray 71997.
10. Heinrich S, Schneider M, inventors; Schneider Heinrich, Schneider Margarete, assignee. Polymorphs of telmisartan. United States Patent US 6358986. 2002 July 18.
11. Giovanni G. Antihypertensive medicaments containing lacidipine and telmisartan. WIPO Patent No. WO/2000/027397A. 2000 May 18.
12. Nakatani M, Ohki T, Takeshi S, Toyoshima K, inventors; Boehringer Ingelheim International GmbH, assignee. Solid pharmaceutical formulations comprising Telmisartan. European Patent EP 1545467. 2007 December 9.
13. Mandić Z, Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal 2006, 41:866-871.
14. Wolfgang G, Hurnaus R, Griss G, Sauter R, Reiffen M, Rupprecht E, inventors; Boehringer Ingelheim KG, assignee. Phenylacetic acid benzylamides. United States Patent US RE 37035. 2001 January 30.
15. Wolfgang G, Hurnaus R, Griss G, Sauter R, Reiffen M, Ruprecht E, inventors; Karl Thomae GmbH, assignee. Phenylacetic acid benzylamides. United States Patent US 5312924. 1994 May 17.
16. Wolfgang G, Hurnaus R, Griss G, Sauter R, Reiffen M, Ruprecht E, inventors; Karl Thomae GmbH, assignee. Phenylacetic acid benzylamides. United States Patent US 6143769. 2000 December 7.
17. Müller PG, inventors; Novo, Nordisk A/s, assignee. NIDDM regimen. United States Patent US 6677358. 2004 January 13.
18. http://www.onlinepharmacynz.com/product/485/Aspro_Clear_Regular_Strength_300mg.html.
19. Kazmierski WM. Antiviral drugs: from basic discovery through clinical trials 2011, Wiley, New Jersey.
20. Singh J, Pudipeddi M, Lindrud MD, inventors; Bristol-Myers Squibb Company, assignee. Bisulfate salt of HIV protease inhibitor. United States Patent US 6087383. 2000 July 11.
21. Béni S, Szakács Z, Csernák O, Barcza L, Noszál B. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. Eur J Pharm Sci 2007, 30:167-174.
22. http://www.rxlist.com/gleevec-drug.htm.
23. Zimmermann J, Sutter B, Burger HM. Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use. WIPO Patent WO/1999/003854. 1999.
24. Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of generic competition by Abbott laboratories[U+05F3] fenofibrate franchise. Arch Intern Med 2012, 172:724-730.
25. http://www.rxlist.com/trilipix-drug.htm.
26. Weatherall MW, Telzerow AJ, Cittadini E, Kaube H, Goadsby PJ. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology 2010, 75:1098-1103.
27. Diener H, Asasumamig Study Group Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999, 19:581-588.
28. Seymour RA, Williams FM, Luyk NM, Boyle MA, Whitfield PM, Nicholson E, et al. Comparative efficacy of soluble aspirin and aspirin tablets in postoperative dental pain. Eur J Clin Pharmacol 1986, 30:495-498.
29. European Medicines Agency. Committee for medicinal products for human use, plenary meeting monthly report, EMEA/CHMP/389326/2009.
30. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/201803s000ltr.pdf.
31. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202172s000ltr.pdf.
32. Patel A, Jones SA, Ferro A, Patel N. Pharmaceutical salts: a formulation trick or a clinical conundrum?. Br J Cardiol 2009, 16:281-286.
33. Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm 2003, 253:111-119.
34. Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur J Pharm Sci 2006, 28:7-14.
35. http://www.rxlist.com/taxol-drug.htm.
36. Hennenfent K, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 2006, 17:735-749.
37. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27:2569-2589.
38. http://www.rxlist.com/taxotere-drug.htm.
39. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022234Orig1s000Approv.pdf.
40. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201525Orig1s000ClinPharmR.pdf.
41. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022312s000ltr.pdf.
42. Powell MF, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol 1998, 52:238-311.
43. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001, 48:27-42.
44. Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. Emerging trends in the stabilization of amorphous drugs. Int J Pharm 2013, 453:65-79.
45. Crisp HA, Clayton JC, Elliott LG, Wilson EM, inventor; Glaxo Group Limited, assignee. Preparation of a highly pure, substantially amorphous form of cefuroxime axetil. United States Patent US 4820833. April 111989.
46. Crisp HA, Clayton JC, inventors; Glaxo Group Limited, assignee. Amorphous form of cefuroxime ester. United States Patent US 4562181. 1985 December 31.
47. Holohan JJ, Edwards IJ, inventors; Imperial Chemical Industries PLC, assignee. Pharmaceutical agents. United States Patent US 5319097. 1994 July 6.
48. Corvari SJ, Creekmore JR, inventors; AstraZeneca UK Limited, assignee. Pharmaceutical compositions comprising Zafirlukast. European Patent EP 1041966. 2003 July 2.
49. Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010, 11:518-527.
50. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000, 50:47-60.
51. Durate I, Temtem M, Gil M, Gaspar F. Overcoming poor bioavailability through amorphous solid dispersions. Ind Pharm 2011, 30:4-6.
52. Miller DA. Improved oral absorption of poorly water-soluble drugs by advanced solid dispersion systems [dissertation]. Austin: University of Texas; 2007.
53. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 2013, 453:101-125.
54. Almarsson Ö, Peterson ML, Zaworotko M. The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents. Pharm Pat Anal 2012, 1:313-327.
55. Rios-Doria J, Carie A, Costich T, Burke B, Skaff H, Panicucci R, et al. A versatile polymer micelle drug delivery system for encapsulation and in vivo stabilization of hydrophobic anticancer drugs. J Drug Deliv 2012, 2012:951741.
56. Riggio C, Pagni E, Raffa V, Cuschieri A. Nano-oncology: clinical application for cancer therapy and future perspectives. J Nanomater 2011, 2011:164506.
57. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014, 190:465-476.
58. Souto EB. Patenting nanomedicines: legal aspects, intellectual property and grant opportunities 2012, Springer Science & Business Media, Berlin Heidelberg.
59. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996, 85:1017-1025.
60. Nekkanti V, Karatgi P, Paruchuri S, Pillai R. Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration. Drug Deliv 2011, 18:294-303.
61. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007, 329:1-11.
62. Gassmann P, List M, Schweitzer A, Sucker H. Hydrosols: alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm 1994, 40:64-72.
63. List M, Sucker H. Pharmaceutical colloidal hydrosols for injection. GB Patent 2200048. 1998.
64. Sucker H, Gassmann P. Improvements in pharmaceutical compositions. GB Patent 2269536A. 1994.
65. Kipp JE, Wong JCT, Doty MJ, Rebbeck CL. Microprecipitation method for preparing submicron suspensions. Google Patents; 2003 January 2.
66. 2 and cryogenic spray-freezing technologies. Drug Dev Ind Pharm 2001, 27:1003-1015.
67. Kauffman GB. The origins of heterogeneous catalysis by platinum: Johann Wolfgang Döbereiner[U+05F3]s contributions. Enantiomer 1999, 4:609-619.
68. Robertson AJB. The development of ideas on heterogeneous catalysis. Platin Met Rev 1983, 27:31-39.
69. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. Recent advances in novel drug delivery systems. J Nanotechnol 2006, 2:1-11.
70. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19.
71. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008, 60:939-954.
72. Mouton JW, Van Peer A, De Beule K, Van Vliet A, Donnelly J, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006, 50:4096-4102.
73. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, et al. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 2004, 44:67-72.
74. Nekkanti V, Vabalaboina V, Pillai R. Drugnanoparticles - an overview. In: Hashim AA, editor. The delivery of nanoparticles. Rijeka: InTech; 2012. Available from: . http://www.intechopen.com/books/the-delivery-of-nanoparticles/drug-nanoparticles-an-overview.
75. Saffie-Siebert R, Ogden J, Parry-Billings M. Nanotechnology approaches to solving the problems of poorly water-soluble drugs. Drug Discov World 2005, 2005:71-76.
76. http://www.pharmafocusasia.com/research_development/sonication_assisted_nanoencapsulation.htm.
77. Miller OJ, Bernath K, Agresti JJ, Amitai G, Kelly BT, Mastrobattista E, et al. Directed evolution by in vitro compartmentalization. Nat Methods 2006, 3:561-570.
78. http://www.aiche.confex.com/aiche/2005/techprogram/P21745.htm.
79. http://www.physorg.com/news3152.html.
80. http://www.liambean.hubpages.com/hub/How-nano-technology-may-be-applied-to-medicine.
81. http://www.phys.org/news154538439.html.
82. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drug. Int J Pharm 2002, 242:121-128.
83. Gasco MR, inventors; Gasco, Maria R, assignee. Method for producing solid lipid microspheres having a narrow size distribution. United States Patent US 5250236. 1993 October 5.
84. Trotta M, Carlotti ME, Gallarate M, Zara GP, Muntoni E, Battaglia L. Insulin-loaded SLN prepared with the emulsion dilution technique:in vivo tracking of nanoparticles after oral administration to rats. J Dispers Sci Technol 2011, 32:1041-1045.
85. Xie SY, Zhu LY, Dong Z, Wang XF, Wang Y, Li XH, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B:Biointerfaces 2011, 83:382-387.
86. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009, 73:1-15.
87. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid nanoparticles for enhancing vinpocetine[U+05F3]s oral bioavailability. J Control Release 2006, 114:53-59.
88. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003, 255:13-32.
89. Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech 2011, 12:712-722.
90. Harms M, Müller-Goymann CC. Solid lipid nanoparticles for drug delivery. J Drug Deliv Sci Technol 2011, 21:89-99.
91. Wei W, Shi SJ, Liu J, Sun X, Ren K, Zhao D, et al. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application. J Drug Target 2010, 18:557-566.
92. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964, 8:660-668.
93. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995, 267:1275-1276.
94. Kalepu S, Sunilkumar KT, Betha S, Mohanvarma M. Liposomal drug delivery system-a comprehensive review. Int J Drug Dev Res 2013, 5:62-75.
95. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 1997, 71:103-107.
96. Sharma A, Bernacki RJ, Straubinger RM, Ojima I. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 1995, 84:1400-1404.
97. Proffitt RT, Adler-Moore J, Chiang SM, Inventors; NeXstar Pharmaceuticals, Inc., Assignee. Amphotericin B liposome preparation. United States Patent US 5965156. 1999 October 12.
98. Lasic DD, Frederik PM, Stuart MCA, Barenholz Y, McIntosh TJ. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett 1992, 312:255-258.
99. Nekkanti V, Venkatesan N, Betageri GV. Proliposomes for oral delivery: progress and challenges. Curr Pharm Biotechnol 2015, 16:1-10.
100. Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, Kandadi P, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm 2012, 80:347-357.
101. Betageri GV, inventors; Western University of Health Sciences, assignee. Proliposomal drug delivery system. United States Patent US 6849269. 2005 April 24.
102. Betageri GV, inventors; Western Center for Drug Development College of Pharmacy Western University of Health Sciences, assignee. Enteric-coated proliposomal formulations for poorly water soluble drugs. United States Patent US 6759058. 2004 July 6.
103. Katare OP, Vyas SP, Dixit VK. Proliposomes of indomethacin for oral administration. J Microencapsul 1991, 8:1-7.
104. Xu HT, He L, Nie SF, Guan J, Zhang XN, Yang XG, et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release 2009, 140:61-68.
105. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005, 103:860-876.
106. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems-an overview. Acta Pharm Sin B 2013, 3:361-372.
107. Bhalani VT, Patel SB, inventors; Sidmak Laboratories, Inc., assignee. Pharmaceutical composition for cyclosporines. United States Patent US 5858401. 1999 January 12.
108. Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010, 62:1622-1636.
109. Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP. Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm 2009, 35:603-611.
110. Shen HR, Zhong MK. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 2006, 58:1183-1191.